These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8585027)

  • 21. Lupus anticoagulants in children.
    Singh AK; Rao KP; Kizer J; Lazarchick J
    Ann Clin Lab Sci; 1988; 18(5):384-7. PubMed ID: 3140708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
    De Bel AV; Van der Cruyssen GA; Devreese KM
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to activated protein C (APCR): reference values of APC-ratios for children.
    Uttenreuther-Fischer MM; Ziemer S; Gaedicke G
    Thromb Haemost; 1996 Nov; 76(5):813-4. PubMed ID: 8950795
    [No Abstract]   [Full Text] [Related]  

  • 24. A prothrombinase-based assay for detection of resistance to activated protein C.
    Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
    Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract.
    Martorell JR; Muñoz-Castillo A; Gil JL
    Thromb Haemost; 1995 Aug; 74(2):796-7. PubMed ID: 8585026
    [No Abstract]   [Full Text] [Related]  

  • 26. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus.
    Tomás JF; Alberca I; Tabernero MD; Cordero M; Del Pino-Montes J; Vicente V
    J Rheumatol; 1998 Jan; 25(1):57-62. PubMed ID: 9458203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low plasma factor XII activity in patients with systemic lupus erythematosus and a lupus anticoagulant.
    Matsuda J; Gotoh M
    Blood Coagul Fibrinolysis; 1997 Jun; 8(4):255-6. PubMed ID: 9199826
    [No Abstract]   [Full Text] [Related]  

  • 28. Antithrombin, protein S and protein C and antiphospholipid antibodies in systemic lupus erythematosus.
    Costallat LT; Ribeiro CC; Annichino-Bizzacchi JM
    Sangre (Barc); 1998 Oct; 43(5):345-8. PubMed ID: 9868323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thromboelastography assessment of coagulation status in parturients with lupus anticoagulant receiving heparin therapy.
    Harnett M; Kodali BS
    Int J Obstet Anesth; 2006 Apr; 15(2):177-8. PubMed ID: 16488131
    [No Abstract]   [Full Text] [Related]  

  • 30. Performance of Platelin LS and dilute Russell's viper venom for the screening of lupus anticoagulant in patients with venous thromboembolism.
    Morelli VM; Rodrigues CA; Noguti MA; Matos MF; da Silveira RC; Ribeiro AA; Lourenço DM
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):401-5. PubMed ID: 17581313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new dilution for the modified APTT-based assay for activated protein C resistance: improvement of the reliability in patients with a lupus anticoagulant.
    Benattar N; Schved JF; Biron-Andréani C
    Thromb Haemost; 2000 Jun; 83(6):967-8. PubMed ID: 10896260
    [No Abstract]   [Full Text] [Related]  

  • 32. Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.
    Vayá A; Santaolaria M; Micó L; Calvo J; Oropesa R; Villa P; Todoli J; Simó M; Corella D; Ricart JM
    Clin Hemorheol Microcirc; 2008; 40(2):79-87. PubMed ID: 19029633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
    Staropoli JF; Van Cott EM; Makar RS
    Transfusion; 2008 Nov; 48(11):2435-41. PubMed ID: 18673345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors.
    Afeltra A; Vadacca M; Conti L; Galluzzo S; Mitterhofer AP; Ferri GM; Del Porto F; Caccavo D; Gandolfo GM; Amoroso A
    Arthritis Rheum; 2005 Jun; 53(3):452-9. PubMed ID: 15934123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The positive rate of lupus anticoagulant according to the each understanding disease in our hospital].
    Omote M; Yoshida T; Asakura H; Ontachi Y; Hayashi T; Morishita E; Yamazaki M; Fujita S; Nakao S
    Rinsho Byori; 2006 Sep; 54(9):903-9. PubMed ID: 17063871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
    Payzin B; Adakan FY; Yalçin HC; Cetinkaya GS; Berkmen S; Eraslan S; Unsal B
    Turk J Gastroenterol; 2006 Sep; 17(3):183-90. PubMed ID: 16941251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coagulation profile in systemic lupus erythematosus studies in 20 patients.
    Boey ML; Tsakok FH; Feng PH
    Singapore Med J; 1985; 26(4-5):361-4. PubMed ID: 4071090
    [No Abstract]   [Full Text] [Related]  

  • 38. Avoiding errors in the laboratory evaluation of potent lupus anticoagulants.
    Penmetsa GK; Rodgers GM; Smock KJ
    Am J Hematol; 2010 Apr; 85(4):272-4. PubMed ID: 20196174
    [No Abstract]   [Full Text] [Related]  

  • 39. [Laboratory diagnosis of lupus anticoagulant].
    Swadźba J; Musiał J; Jankowski M; Bednarczyk M; Dyczek A; Szczeklik A
    Pol Merkur Lekarski; 1996 Nov; 1(5):359-62. PubMed ID: 9273219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The lupus inhibitor].
    Carreras LO; Vermylen J
    Sangre (Barc); 1981; 26(5-A):610-8. PubMed ID: 6798699
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.